US 12,128,049 B2
Dosage regimen of paliperidone palmitate extended-release injectable suspension
Youxin Li, Shandong (CN); Chunjie Sha, Shandong (CN); Fengjuan Zhao, Shandong (CN); Changbing Tu, Shandong (CN); Kaoxiang Sun, Shandong (CN); Wanhui Liu, Shandong (CN); Lifang Sun, Shandong (CN); and Ying Meng, Shandong (CN)
Assigned to Luye Innomind Pharma Shijiazhuang Co., Ltd., Shijiazhuang (CN)
Filed by Luye Innomind Pharma Shijiazhuang Co., Ltd., Shijiazhuang (CN)
Filed on Apr. 21, 2023, as Appl. No. 18/305,303.
Application 18/305,303 is a continuation of application No. 16/759,287, granted, now 11,666,573, previously published as PCT/US2018/057858, filed on Oct. 26, 2018.
Claims priority of provisional application 62/647,333, filed on Mar. 23, 2018.
Claims priority of provisional application 62/578,082, filed on Oct. 27, 2017.
Prior Publication US 2023/0248732 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0019 (2013.01)] 23 Claims
 
1. A dosing regimen for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders, the dosing regimen consisting of:
(1) administering intramuscularly to the patient an initial dose of 312 mg-468 mg paliperidone palmitate on the first day of treatment; and
(2) beginning on the 29th day±7 days from the initial dose, administering intramuscularly to the patient one or more monthly doses in the range of 39 mg to 234 mg paliperidone palmitate, wherein each dose of paliperidone palmitate is formulated in an aqueous suspension formulation.